DNA
Ginkgo Bioworks Holdings, Inc.
There isn't enough reported data to score DNA yet.
DNA Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Unavailable |
DNA's revenue, profitability and cash flow are currently weak. There isn't enough data to rate its balance sheet.
DNA PE Valuation
DNA has no meaningful PE right now: it lost money over the past year.
DNA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Moderate |
Analysts expect DNA's losses to grow, with revenue declining.
DNA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$4.19 | +$1.90 |
| Q2 2026 | -$5.00 | +$0.72 |
| Q1 2026 | -$5.35 | +$3.67 |
| Q4 2025 | -$5.64 | +$4.90 |
| Q3 2025 | -$6.09 | +$6.59 |
| Q2 2025 | -$5.72 | +$12.28 |
| Q1 2025 | -$9.02 | +$8.18 |
| Q4 2024 | -$10.54 | +$7.86 |
DNA is still losing money, but far less than before: $4.19 per share over the past year, against $96.00 at its worst in late 2022.
DNA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $27.7M | -29% |
| Q2 2026 | $20.2M | -59% |
| Q1 2026 | $19.5M | -60% |
| Q4 2025 | $33.4M | -24% |
| Q3 2025 | $38.8M | -56% |
| Q2 2025 | $49.6M | -12% |
| Q1 2025 | $48.3M | +27% |
| Q4 2024 | $43.8M | +26% |
DNA's revenue has slid since its 2022 peak: $28M last quarter, down 29% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -157% | +74 points |
| Q2 2026 | -290% | -158 points |
| Q1 2026 | -367% | -182 points |
| Q4 2025 | -212% | +24 points |
| Q3 2025 | -232% | -170 points |
| Q2 2025 | -132% | +265 points |
| Q1 2025 | -184% | +285 points |
| Q4 2024 | -236% | +276 points |
DNA's operating margin was −157% last quarter, up 74 points from the same quarter a year ago.
DNA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$30.3M | +$1.3M |
| Q2 2026 | -$46.9M | -$6.6M |
| Q1 2026 | -$48.6M | +$10.5M |
| Q4 2025 | -$47.7M | +$8.5M |
| Q3 2025 | -$31.6M | +$87M |
| Q2 2025 | -$40.3M | +$71.1M |
| Q1 2025 | -$59.1M | +$36.8M |
| Q4 2024 | -$56.1M | +$5.1M |
DNA has burned cash in almost every quarter: −$174M over the past year, against −$187M the year before.
DNA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3% | +1.9M shares |
| 1 year | +15% | +8.3M shares |
| 3 years | +31% | +15.2M shares |
| 5 years | +99% | +31.8M shares |
DNA has 64M diluted shares, up 15% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
| Q4 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
DNA Net Leverage
DNA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
DNA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.4 | Neutral |
| Stochastic | 37.8 | Neutral |
DNA's weekly RSI is 53 (neutral) and its Stochastic is 38 (neutral).
DNA PE vs Healthcare Sector
DNA has no meaningful PE right now: it lost money over the past year.
DNA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.1 | 8% below |
| 20 week MA | $9.13 | 12% above |
| 50 week MA | $8.69 | 18% above |
| 100 week MA | $9.47 | 8% above |
| 200 week MA | $27.5 | 63% below |
DNA's trend is mixed: it's above three of its five weekly moving averages, and 63% below its 200-week average.
DNA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $414.8 | $426.8 | +2.9% |
| 2022 | $426.8 | $66.4 | -84% |
| 2023 | $66.4 | $67.6 | +1.8% |
| 2024 | $67.6 | $9.66 | -86% |
| 2025 | $9.66 | $8.40 | -13% |
| 2026 YTD | $8.40 | $10.2 | +22% |
DNA has finished lower in three of the last five years. It's up 22% so far in 2026.